SCHEMBL30775237

SCHEMBL30775237

NC(=O)CN1CCC(Oc2ccncn2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.37
CHRM3 P20309 1/20 0.37
PRKCI P41743 2/20 0.37
IRAK4 Q9NWZ3 2/20 0.37
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
EGFR P00533 4/20 0.35
ABL1 P00519 2/20 0.35
SRC P12931 2/20 0.35
ABL2 P42684 2/20 0.35
MDM2 Q00987 1/20 0.35
RPS6KB1 P23443 2/20 0.35
LIPG Q9Y5X9 1/20 0.35
FAAH O00519 1/20 0.35
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
ERBB2 P04626 1/20 0.34
KDM5A P29375 1/20 0.34
OPRK1 P41145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775382 0.91 GRIN1 (0.38) PRKCIMDM2FAAHGRIN1GRIN2B
SCHEMBL30775264 0.85 KDM5A (0.47) CHRM2CHRM3IRAK4MEN1HTT
SCHEMBL30775274 0.84 ERBB2 (0.44) IRAK4MEN1HTTKMT2AEGFR
SCHEMBL30775305 0.82 GRIN1 (0.48) CHRM2IRAK4GRIN1GRIN2B
SCHEMBL30775207 0.82 CHRM2 (0.47) CHRM2CHRM3PRKCIGRIN1GRIN2B
SCHEMBL30775184 0.80 EGFR (0.38) IRAK4EGFRABL1SRCABL2
SCHEMBL30775317 0.78 CHRM2 (0.37) CHRM2CHRM3PRKCIIRAK4MEN1
SCHEMBL30775332 0.78 CHRM2 (0.37) CHRM2CHRM3PRKCIIRAK4OPRK1
SCHEMBL30775258 0.77 EPHX2 (0.50) MEN1HTTKMT2AEGFRERBB2
SCHEMBL31347634 0.77 CCNK (0.37) PRKCIIRAK4MEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CHRM2 4705/4885CHRM3 4760/4885PRKCI 3234/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CHRM2 4705/4885CHRM3 4760/4885PRKCI 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.